MR. GENE - BEST PRICE DNA
DEAD

Serial Number

77329472

Owner

Mr. Gene GMBH

Attorney

Phil Makrogiannis

Filing Date

Nov 14, 2007

Add to watchlist:

No watchlists yet
View on USPTO

MR. GENE - BEST PRICE DNA Trademark

Serial Number: 77329472 • Registration: 3681939

MR. GENE - BEST PRICE DNA is a trademark filed by Mr. Gene GMBH on November 14, 2007. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 7 (Machinery), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Mr. Gene GMBH

Im Gewerbepark B32
Regensburg 93059 , DE

Entity Type: 99

Trademark Details

Filing Date

November 14, 2007

Registration Date

September 15, 2009

Published for Opposition

June 30, 2009

Cancellation Date

April 22, 2016

Goods & Services

Scientific and laboratory equipment, namely, automatic machines for the synthesis of deoxyribonucleic acids; robot machines for laboratory purposes; computer terminals; computer programs for use in database management in the fields of biotechnology and molecular biology; computer software to increase potency of enzymes and enzyme preparations, bacteria preparations, bacteriological preparations, micro-organism cultures, biological preparations, diagnostic preparations; computer operating programs; computer peripheral devices; computer keyboards; blank magnetic data carriers; blank optical disks; data processors; computer memories; blank floppy disks; blank hard drives for computers; printers for use with computers; computer interface boards; laptop computers; data processors, namely, readers and scanners; computer mouse; semiconductors; computer modems; computer monitors; computer hardware; and notebook computers; pressure regulators for use in controlling the flow of cryogenic liquids

Filling machines; membranes for use with electric pumps; mixing machines; electric pumps; regulators being parts of machines; industrial robot machines; centrifugal separator machines

medicines for human-medical purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes for use in the treatment of cancer, diabetes, Alzheimer's and infectious diseases; medicines for dental purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes for use in the treatment of cancer, Alzheimer's and infectious diseases; medicines for veterinary purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes for use in the treatment of cancer, diabetes, Alzheimer's and infectious diseases; bacteriological preparations for medical and veterinary purposes for use in the treatment of cancer, high blood pressure, diarrhea, skin irritations, infections, diabetes, autoimmune diseases and arthritis as well as for use in gene therapy; biological preparations for medical purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes for use in the treatment of cancer, diabetes, Alzheimer's and infectious diseases; biological preparations for veterinary purposes, namely, antibiotics, antibodies, DNA, RNA, vaccines, blood-producing preparations, hormones and enzymes for use in the treatment of cancer, diabetes, Alzheimer's and infectious diseases; germicides for medical and laboratory equipment, institutional, domestic uses; vermicides for medical and laboratory equipment, institutional, domestic, residential uses; fungicides for medical and laboratory equipment, institutional, domestic uses; biological materials for medical diagnostic laboratories, namely, proteins, genes, especially genes comprising 80 to 150 base pairs, DNA, especially deoxyribonucleic acid comprising 80 to 150 base pairs, RNA and modifications thereof; diagnostic materials for clinical and medical laboratory purposes, namely, proteins, genes, especially genes comprising 80 to 150 base pairs, DNA, especially deoxyribonucleic acid comprising 80 to 150 base pairs, RNA and modifications thereof; pharmaceutical preparations for clinical and medical laboratory purposes, namely, deoxyribonucleic acid, especially deoxyribonucleic acid comprising 80 to 150 base pairs and genes, especially genes comprising 80 to 150 base pairs

chemical preparations for laboratory analysis in the field of biotechnology, drug discovery, genomics, molecular biology and microbiology; chemical preparations for scientific purposes in the field of biotechnology, drug discovery, genomics, molecular biology and microbiology; bacteria preparations for use in food manufacture, waste water treatment, fermentation, research, manufacture of cosmetics, manufacture of scientific compounds, manufacture of pharmaceutical compounds; bacteriological preparations for use in food manufacture, waste water treatment, fermentation, research, manufacture of cosmetics, manufacture of scientific compounds, manufacture of pharmaceutical compounds; micro-organism cultures for use in food manufacture, waste water treatment, fermentation, research, manufacture of cosmetics, manufacture of scientific compounds, manufacture of pharmaceutical compounds; biochemical catalysts for use in food manufacture, waste water treatment, fermentation, research, manufacture of cosmetics, manufacture of scientific compounds, manufacture of pharmaceutical compounds; biological materials for scientific and research laboratories, namely, proteins, genes, especially genes comprising 80 to 150 base pairs, DNA, especially deoxyribonucleic acid comprising 80 to 150 base pairs, RNA and modifications thereof; diagnostic materials for scientific and research purposes, namely, proteins, genes, especially genes comprising 80 to 150 base pairs, DNA, especially deoxyribonucleic acid comprising 80 to 150 base pairs, RNA and modifications thereof; enzymes and enzyme preparations for use in the field of food manufacture, waste treatment, fermentation, manufacture of cosmetics, manufacture of scientific compounds, manufacture of pharmaceutical compounds; genetic materials for scientific and research purposes, namely, deoxyribonucleic acid, especially deoxyribonucleic acid comprising 80 to 150 base pairs and genes, especially genes comprising 80 to 150 base pairs

Computer services, namely, updating of computer software for others, consulting in the field of biotechnology, designing computer software for others, maintenance of computer software for others, leasing of computer software, computer programming for others, leasing of computers, and recovery of computer data; chemical analysis for others; research for others in the fields of bacteriology, biology, chemistry, physics, genealogy, cosmetics, engineering, and machine engineering; laboratory services for others in the fields of bacteriology and chemistry; consultation in the fields of bacteriology, biology, chemistry, physics, genealogy, cosmetics research, engineering and machine engineering; consultancy pertaining to pharmacology; measuring calibration for others; development and research of new products for others; technical consultation in the field of environmental assessment, compliance and planning; technical project planning and consulting services in the fields of bacteriology, biology, chemistry, physics, genealogy research, engineering, and machine engineering; technical project planning and consulting services regarding laboratory research in the field of cosmetics; and quality control for others

Filing History

CANCELLED SEC. 8 (6-YR)
Apr 22, 2016 C8..
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 23, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 23, 2014 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 21, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 21, 2011 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 2, 2011 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 2, 2011 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 1, 2011 TCCA
REGISTERED-PRINCIPAL REGISTER
Sep 15, 2009 R.PR
PUBLISHED FOR OPPOSITION
Jun 30, 2009 PUBO
NOTICE OF PUBLICATION
Jun 10, 2009 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 26, 2009 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
May 18, 2009 CNSA
EXAMINER'S AMENDMENT ENTERED
May 18, 2009 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 18, 2009 GNEN
EXAMINERS AMENDMENT E-MAILED
May 18, 2009 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 18, 2009 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 6, 2009 GNRN
NON-FINAL ACTION E-MAILED
May 6, 2009 GNRT
NON-FINAL ACTION WRITTEN
May 6, 2009 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 29, 2009 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Apr 17, 2009 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 8, 2009 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 7, 2009 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 23, 2009 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 20, 2009 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 20, 2009 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 20, 2009 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 27, 2008 GNFN
FINAL REFUSAL E-MAILED
Sep 27, 2008 GNFR
FINAL REFUSAL WRITTEN
Sep 27, 2008 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 8, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 8, 2008 CRFA
ASSIGNED TO LIE
Sep 8, 2008 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 28, 2008 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 6, 2008 GNRN
NON-FINAL ACTION E-MAILED
Mar 6, 2008 GNRT
NON-FINAL ACTION WRITTEN
Mar 6, 2008 CNRT
ASSIGNED TO EXAMINER
Feb 28, 2008 DOCK
NEW APPLICATION ENTERED
Nov 19, 2007 NWAP